April 16 (Reuters) - Mayne Pharma Group Ltd (MYX) :
- MAYNE PHARMA SUBMITS NEW DRUG APPLICATION FOR E4/DRSP TO THE FDA
- NDA TO FDA SEEKS MARKETING AUTHORISATION FOR E4/DRSP, A COMBINED ORAL CONTRACEPTIVE INDICATED FOR PREVENTION OF PREGNANCY
- IF APPROVED BY FDA, E4/DRSP IS EXPECTED TO BE MADE AVAILABLE TO PATIENTS IN US MARKET IN FIRST HALF OF CALENDAR 2021.
News: MYX Mayne Pharma Submits New Drug Application For E4/DRSP To FDA
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.08 |
Change
0.010(0.20%) |
Mkt cap ! $412.7M | |||
| Open | High | Low | Value | Volume |
| $5.13 | $5.15 | $5.08 | $445.2K | 87.01K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 810 | $5.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.15 | 2033 | 2 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| MYX (ASX) Chart |